Phosphodiesterase 5 inhibitors: current status and potential applications (Q34147460)

31 July 2017

1 reference

title

Phosphodiesterase 5 inhibitors: current status and potential applications (English)

1 reference

31 July 2017

David P Rotella

1 reference

31 July 2017

publication date

1 September 2002

1 reference

Nature Reviews Drug Discovery

31 July 2017

published in

1 reference

31 July 2017

1 reference

31 July 2017

1 reference

31 July 2017

page(s)

674-682

1 reference

Cyclic GMP phosphodiesterase-5: target of sildenafil

31 July 2017

cites work

1 reference

Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A

21 January 2018

1 reference

Expression of three isoforms of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in human penile cavernosum

21 January 2018

1 reference

Expression, structure and chromosomal localization of the human cGMP-binding cGMP-specific phosphodiesterase PDE5A gene

21 January 2018

1 reference

Isolation and characterization of cDNAs encoding PDE5A, a human cGMP-binding, cGMP-specific 3',5'-cyclic nucleotide phosphodiesterase

21 January 2018

1 reference

Hydropathic analysis and mutagenesis of the catalytic domain of the cGMP-binding cGMP-specific phosphodiesterase (PDE5). cGMP versus cAMP substrate selectivity

21 January 2018

1 reference

21 January 2018

1 reference

Effect of sildenafil in patients with erectile dysfunction taking antihypertensive therapy. Sildenafil Study Group

21 January 2018

1 reference

Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease

21 January 2018

1 reference

Efficacy and safety of oral sildenafil (Viagra) in men with erectile dysfunction caused by spinal cord injury.

21 January 2018

1 reference

An open trial of oral sildenafilin antidepressant-induced sexual dysfunction

21 January 2018

1 reference

Sildenafil (VIAGRATM), a potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunction

21 January 2018

1 reference

Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: a RigiScan and pharmacokinetic study

21 January 2018

1 reference

The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial

21 January 2018

1 reference

FR226807: a potent and selective phosphodiesterase type 5 inhibitor

21 January 2018

1 reference

Pharmacological profile of T-1032, a novel specific phosphodiesterase type 5 inhibitor, in isolated rat aorta and rabbit corpus cavernosum

21 January 2018

1 reference

T-1032, a novel specific phosphodiesterase type 5 inhibitor, increases venous compliance in anesthetized rats

21 January 2018

1 reference

Novel, potent, and selective phosphodiesterase 5 inhibitors: synthesis and biological activities of a series of 4-aryl-1-isoquinolinone derivatives

21 January 2018

1 reference

KF31327, a new potent and selective inhibitor of cyclic nucleotide phosphodiesterase 5.

21 January 2018

1 reference

Synthesis and phosphodiesterase 5 inhibitory activity of novel phenyl ring modified sildenafil analogues

21 January 2018

1 reference

Synthesis and phosphodiesterase 5 inhibitory activity of new 5-phenyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one derivatives containing an N-acylamido group phenyl ring

21 January 2018

1 reference

Synthesis and phosphodiesterase inhibitory activity of new sildenafil analogues containing a carboxylic acid group in the 5'-sulfonamide moiety of a phenyl ring

21 January 2018

1 reference

The discovery of novel, potent and selective PDE5 inhibitors

21 January 2018

1 reference

Sildenafil relaxes rabbit clitoral corpus cavernosum.

21 January 2018

1 reference

Sildenafil augments pelvic nerve-mediated female genital sexual arousal in the anesthetized rabbit

21 January 2018

1 reference

Safety and efficacy of sildenafil in postmenopausal women with sexual dysfunction

21 January 2018

1 reference

A cyclic nucleotide PDE5 inhibitor corrects defective mucin secretion in submandibular cells containing antibody directed against the cystic fibrosis transmembrane conductance regulator protein

21 January 2018

1 reference

Effects of sildenafil on esophageal motility of patients with idiopathic achalasia

21 January 2018

1 reference

Sildenafil inhibits gastroduodenal motility

21 January 2018

1 reference

Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension

21 January 2018

1 reference

Cerebrovascular dysfunction after subarachnoid haemorrhage: novel mechanisms and directions for therapy

21 January 2018

1 reference

Modulation of human platelet aggregation by the phosphodiesterase type 5 inhibitor sildenafil

21 January 2018

1 reference

Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions

21 January 2018

1 reference

Phosphorylation of phosphodiesterase-5 by cyclic nucleotide-dependent protein kinase alters its catalytic and allosteric cGMP-binding activities

21 January 2018

1 reference

Sildenafil: study of a novel oral treatment for erectile dysfunction in diabetic men

21 January 2018

1 reference

Imidazo[5,1-f]triazin-4(3H)-ones, a new class of potent PDE 5 inhibitors

21 January 2018

1 reference

Granulocytic sarcoma presenting as testicular and paratesticular masses in infancy

21 January 2018

1 reference

Erectogenic effect of the selective phosphodiesterase type 5 inhibitor, DA-8159

21 January 2018

1 reference

Characterization and effects of methyl-2- (4-aminophenyl)-1, 2-dihydro-1-oxo-7- (2-pyridinylmethoxy)-4-(3,4, 5-trimethoxyphenyl)-3-isoquinoline carboxylate sulfate (T-1032), a novel potent inhibitor of cGMP-binding cGMP-specific phosphodiesterase (P

21 January 2018

1 reference

N-3-substituted imidazoquinazolinones: potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction

21 January 2018

1 reference

Substituted pyrazolopyridines as potent and selective PDE5 inhibitors: potential agents for treatment of erectile dysfunction

21 January 2018

1 reference

IC351 (tadalafil, Cialis): update on clinical experience

21 January 2018

1 reference

Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (Type 5) by sildenafil and related compounds

31 March 2020

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/NRD893

1 reference

31 July 2017

1 reference